id
stringlengths 15
19
| document_id
stringlengths 15
19
| passages
list | entities
list | events
list | coreferences
list | relations
list |
|---|---|---|---|---|---|---|
split_0_train_5000
|
split_0_train_5000
|
[
{
"id": "split_0_train_5000_passage",
"type": "progene_text",
"text": [
"Synthesis of Cbl itself is under control of the CysB protein , and the CysB protein may therefore be regarded as the master regulator for sulfur assimilation in E. coli , while the Cbl protein functions as an accessory element specific for utilization of sulfur from organosulfur sources ."
],
"offsets": [
[
0,
289
]
]
}
] |
[
{
"id": "split_0_train_8069_entity",
"type": "progene_text",
"text": [
"Cbl"
],
"offsets": [
[
13,
16
]
],
"normalized": []
},
{
"id": "split_0_train_8070_entity",
"type": "progene_text",
"text": [
"CysB"
],
"offsets": [
[
48,
52
]
],
"normalized": []
},
{
"id": "split_0_train_8071_entity",
"type": "progene_text",
"text": [
"CysB"
],
"offsets": [
[
71,
75
]
],
"normalized": []
},
{
"id": "split_0_train_8072_entity",
"type": "progene_text",
"text": [
"Cbl"
],
"offsets": [
[
181,
184
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5001
|
split_0_train_5001
|
[
{
"id": "split_0_train_5001_passage",
"type": "progene_text",
"text": [
"Genomic organization and promoter analysis of human KCNN3 gene ."
],
"offsets": [
[
0,
64
]
]
}
] |
[
{
"id": "split_0_train_8073_entity",
"type": "progene_text",
"text": [
"KCNN3"
],
"offsets": [
[
52,
57
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5002
|
split_0_train_5002
|
[
{
"id": "split_0_train_5002_passage",
"type": "progene_text",
"text": [
"KCNN3 is a member of the gene family , KCNN1-4 , encoding the small and intermediate conductance calcium - activated potassium channels ."
],
"offsets": [
[
0,
137
]
]
}
] |
[
{
"id": "split_0_train_8074_entity",
"type": "progene_text",
"text": [
"KCNN3"
],
"offsets": [
[
0,
5
]
],
"normalized": []
},
{
"id": "split_0_train_8075_entity",
"type": "progene_text",
"text": [
"KCNN1-4"
],
"offsets": [
[
39,
46
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5003
|
split_0_train_5003
|
[
{
"id": "split_0_train_5003_passage",
"type": "progene_text",
"text": [
"Long CAG-repeat alleles of this gene have been found to be over - represented in patients with schizophrenia in a number of population - based association studies , and this gene maps to human chromosome 1q21 , a region recently implicated in schizophrenia by linkage ."
],
"offsets": [
[
0,
269
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5004
|
split_0_train_5004
|
[
{
"id": "split_0_train_5004_passage",
"type": "progene_text",
"text": [
"To set the stage for a further functional evaluation of KCNN3 , we defined the nature of the genomic locus in the size , structure , and sequence of its introns and exons and the function of potential upstream regulatory regions ."
],
"offsets": [
[
0,
230
]
]
}
] |
[
{
"id": "split_0_train_8076_entity",
"type": "progene_text",
"text": [
"KCNN3"
],
"offsets": [
[
56,
61
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5005
|
split_0_train_5005
|
[
{
"id": "split_0_train_5005_passage",
"type": "progene_text",
"text": [
"We isolated P1 - derived artificial chromosome ( PAC ) clones from a genomic library and identified an overlapping available bacterial artificial chromosome ( BAC ) clone ."
],
"offsets": [
[
0,
172
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5006
|
split_0_train_5006
|
[
{
"id": "split_0_train_5006_passage",
"type": "progene_text",
"text": [
"Cosmids subcloned from the PAC and BAC clones were then sequenced and merged with the sequence in the public database ."
],
"offsets": [
[
0,
119
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5007
|
split_0_train_5007
|
[
{
"id": "split_0_train_5007_passage",
"type": "progene_text",
"text": [
"The KCNN3 gene spans over 163.1 kb and is composed of eight exons and seven introns ."
],
"offsets": [
[
0,
85
]
]
}
] |
[
{
"id": "split_0_train_8077_entity",
"type": "progene_text",
"text": [
"KCNN3"
],
"offsets": [
[
4,
9
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5008
|
split_0_train_5008
|
[
{
"id": "split_0_train_5008_passage",
"type": "progene_text",
"text": [
"All of the exon - intron junctions conform closely to consensus splice sites ."
],
"offsets": [
[
0,
78
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5009
|
split_0_train_5009
|
[
{
"id": "split_0_train_5009_passage",
"type": "progene_text",
"text": [
"The proximal 2.5 kb of the 5' - flanking sequence was obtained and analyzed for potential transcription factor binding sites ."
],
"offsets": [
[
0,
126
]
]
}
] |
[
{
"id": "split_0_train_8078_entity",
"type": "progene_text",
"text": [
"transcription factor"
],
"offsets": [
[
90,
110
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5010
|
split_0_train_5010
|
[
{
"id": "split_0_train_5010_passage",
"type": "progene_text",
"text": [
"In the proximal 2.5 kb upstream region , potential sites for the Ikaros factor ( IK2 ) , homeodomain factor Nkx-2.5 / Csx ( NKX25 ) , nuclear factor of activated T-cells ( NFAT ) , upstream stimulating factor ( USF ) , c-AMP responsive element binding protein ( CREB ) , POU factor Brn2 ( BRN-2 ) , myeloid zinc finger protein ( MZF1 ) , vitellogenin binding protein ( VBP ) , HNF3 forkhead homologue 2 ( HFH2 ) , and transcription initiation were identified , as well as several potential AP-1 and AP-4 sites ."
],
"offsets": [
[
0,
511
]
]
}
] |
[
{
"id": "split_0_train_8079_entity",
"type": "progene_text",
"text": [
"Ikaros factor"
],
"offsets": [
[
65,
78
]
],
"normalized": []
},
{
"id": "split_0_train_8080_entity",
"type": "progene_text",
"text": [
"IK2"
],
"offsets": [
[
81,
84
]
],
"normalized": []
},
{
"id": "split_0_train_8081_entity",
"type": "progene_text",
"text": [
"Nkx-2.5"
],
"offsets": [
[
108,
115
]
],
"normalized": []
},
{
"id": "split_0_train_8082_entity",
"type": "progene_text",
"text": [
"Csx"
],
"offsets": [
[
118,
121
]
],
"normalized": []
},
{
"id": "split_0_train_8083_entity",
"type": "progene_text",
"text": [
"NKX25"
],
"offsets": [
[
124,
129
]
],
"normalized": []
},
{
"id": "split_0_train_8084_entity",
"type": "progene_text",
"text": [
"nuclear factor of activated T-cells"
],
"offsets": [
[
134,
169
]
],
"normalized": []
},
{
"id": "split_0_train_8085_entity",
"type": "progene_text",
"text": [
"NFAT"
],
"offsets": [
[
172,
176
]
],
"normalized": []
},
{
"id": "split_0_train_8086_entity",
"type": "progene_text",
"text": [
"upstream stimulating factor"
],
"offsets": [
[
181,
208
]
],
"normalized": []
},
{
"id": "split_0_train_8087_entity",
"type": "progene_text",
"text": [
"USF"
],
"offsets": [
[
211,
214
]
],
"normalized": []
},
{
"id": "split_0_train_8088_entity",
"type": "progene_text",
"text": [
"c-AMP responsive element binding protein"
],
"offsets": [
[
219,
259
]
],
"normalized": []
},
{
"id": "split_0_train_8089_entity",
"type": "progene_text",
"text": [
"CREB"
],
"offsets": [
[
262,
266
]
],
"normalized": []
},
{
"id": "split_0_train_8090_entity",
"type": "progene_text",
"text": [
"Brn2"
],
"offsets": [
[
282,
286
]
],
"normalized": []
},
{
"id": "split_0_train_8091_entity",
"type": "progene_text",
"text": [
"BRN-2"
],
"offsets": [
[
289,
294
]
],
"normalized": []
},
{
"id": "split_0_train_8092_entity",
"type": "progene_text",
"text": [
"myeloid zinc finger protein"
],
"offsets": [
[
299,
326
]
],
"normalized": []
},
{
"id": "split_0_train_8093_entity",
"type": "progene_text",
"text": [
"MZF1"
],
"offsets": [
[
329,
333
]
],
"normalized": []
},
{
"id": "split_0_train_8094_entity",
"type": "progene_text",
"text": [
"vitellogenin binding protein"
],
"offsets": [
[
338,
366
]
],
"normalized": []
},
{
"id": "split_0_train_8095_entity",
"type": "progene_text",
"text": [
"VBP"
],
"offsets": [
[
369,
372
]
],
"normalized": []
},
{
"id": "split_0_train_8096_entity",
"type": "progene_text",
"text": [
"HNF3 forkhead homologue 2"
],
"offsets": [
[
377,
402
]
],
"normalized": []
},
{
"id": "split_0_train_8097_entity",
"type": "progene_text",
"text": [
"HFH2"
],
"offsets": [
[
405,
409
]
],
"normalized": []
},
{
"id": "split_0_train_8098_entity",
"type": "progene_text",
"text": [
"AP-1"
],
"offsets": [
[
490,
494
]
],
"normalized": []
},
{
"id": "split_0_train_8099_entity",
"type": "progene_text",
"text": [
"AP-4"
],
"offsets": [
[
499,
503
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5011
|
split_0_train_5011
|
[
{
"id": "split_0_train_5011_passage",
"type": "progene_text",
"text": [
"Finally , a 2261 - bp fragment of this upstream region was cloned into a promoterless pGL3 - luciferase vector , where it produced orientation - dependent expression of the reporter gene in transiently transfected PC12 cells , cells which natively express functional KCNN3 channels , suggesting that this cloned fragment includes competent promoter elements of this gene ."
],
"offsets": [
[
0,
372
]
]
}
] |
[
{
"id": "split_0_train_8100_entity",
"type": "progene_text",
"text": [
"luciferase"
],
"offsets": [
[
93,
103
]
],
"normalized": []
},
{
"id": "split_0_train_8101_entity",
"type": "progene_text",
"text": [
"KCNN3"
],
"offsets": [
[
267,
272
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5012
|
split_0_train_5012
|
[
{
"id": "split_0_train_5012_passage",
"type": "progene_text",
"text": [
"Combined transductional and transcriptional targeting of melanoma cells by artificial virus - like particles ."
],
"offsets": [
[
0,
110
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5013
|
split_0_train_5013
|
[
{
"id": "split_0_train_5013_passage",
"type": "progene_text",
"text": [
"BACKGROUND :"
],
"offsets": [
[
0,
12
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5014
|
split_0_train_5014
|
[
{
"id": "split_0_train_5014_passage",
"type": "progene_text",
"text": [
"Artificial virus - like particles ( AVPs ) represent a novel type of liposomal vector resembling retroviral envelopes ."
],
"offsets": [
[
0,
119
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5015
|
split_0_train_5015
|
[
{
"id": "split_0_train_5015_passage",
"type": "progene_text",
"text": [
"AVPs are serum - resistant and non - toxic and can be endowed with a peptide ligand as a targeting device ."
],
"offsets": [
[
0,
107
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5016
|
split_0_train_5016
|
[
{
"id": "split_0_train_5016_passage",
"type": "progene_text",
"text": [
"The vitronectin receptor , alphavbeta3 - integrin , is commonly upregulated on malignant melanoma cells ."
],
"offsets": [
[
0,
105
]
]
}
] |
[
{
"id": "split_0_train_8102_entity",
"type": "progene_text",
"text": [
"vitronectin receptor"
],
"offsets": [
[
4,
24
]
],
"normalized": []
},
{
"id": "split_0_train_8103_entity",
"type": "progene_text",
"text": [
"alphavbeta3 - integrin"
],
"offsets": [
[
27,
49
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5017
|
split_0_train_5017
|
[
{
"id": "split_0_train_5017_passage",
"type": "progene_text",
"text": [
"In the present study we investigated whether AVPs carrying cyclic peptides with an RGD integrin binding motif ( RGD-AVPs ) are suitable for the specific and efficient transduction of human melanoma cells ."
],
"offsets": [
[
0,
205
]
]
}
] |
[
{
"id": "split_0_train_8104_entity",
"type": "progene_text",
"text": [
"integrin"
],
"offsets": [
[
87,
95
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5018
|
split_0_train_5018
|
[
{
"id": "split_0_train_5018_passage",
"type": "progene_text",
"text": [
"METHODS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5019
|
split_0_train_5019
|
[
{
"id": "split_0_train_5019_passage",
"type": "progene_text",
"text": [
"Plasmid DNA was complexed with low molecular weight non - linear polyethyleneimine and packaged into anionic liposomes ."
],
"offsets": [
[
0,
120
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5020
|
split_0_train_5020
|
[
{
"id": "split_0_train_5020_passage",
"type": "progene_text",
"text": [
"Transduction efficiencies were determined after transient transfection of different cell lines in serum - free medium using green fluorescent protein or luciferase reporter genes ."
],
"offsets": [
[
0,
180
]
]
}
] |
[
{
"id": "split_0_train_8105_entity",
"type": "progene_text",
"text": [
"green fluorescent protein"
],
"offsets": [
[
124,
149
]
],
"normalized": []
},
{
"id": "split_0_train_8106_entity",
"type": "progene_text",
"text": [
"luciferase"
],
"offsets": [
[
153,
163
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5021
|
split_0_train_5021
|
[
{
"id": "split_0_train_5021_passage",
"type": "progene_text",
"text": [
"RESULTS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5022
|
split_0_train_5022
|
[
{
"id": "split_0_train_5022_passage",
"type": "progene_text",
"text": [
"We demonstrated that RGD - AVPs transduced human melanoma cells with high efficiencies of > 60 % ."
],
"offsets": [
[
0,
98
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5023
|
split_0_train_5023
|
[
{
"id": "split_0_train_5023_passage",
"type": "progene_text",
"text": [
"Efficient transduction was clearly dependent on the presence of the cyclic RGD ligand and was selective for melanoma cells ."
],
"offsets": [
[
0,
124
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5024
|
split_0_train_5024
|
[
{
"id": "split_0_train_5024_passage",
"type": "progene_text",
"text": [
"The specificity of the vector system could be further enhanced by using the melanocyte - specific tyrosinase promoter to drive transgene expression ."
],
"offsets": [
[
0,
149
]
]
}
] |
[
{
"id": "split_0_train_8107_entity",
"type": "progene_text",
"text": [
"tyrosinase"
],
"offsets": [
[
98,
108
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5025
|
split_0_train_5025
|
[
{
"id": "split_0_train_5025_passage",
"type": "progene_text",
"text": [
"CONCLUSION :"
],
"offsets": [
[
0,
12
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5026
|
split_0_train_5026
|
[
{
"id": "split_0_train_5026_passage",
"type": "progene_text",
"text": [
"Our findings suggest that the AVP technology is a useful approach for generating highly efficient and specific non - viral vectors for melanoma targeting , in particular in a setting of combined transductional and transcriptional targeting ."
],
"offsets": [
[
0,
241
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5027
|
split_0_train_5027
|
[
{
"id": "split_0_train_5027_passage",
"type": "progene_text",
"text": [
"Developmental regulation and overexpression of the transcription factor AP-2 , a potential regulator of the timing of Schwann cell generation ."
],
"offsets": [
[
0,
143
]
]
}
] |
[
{
"id": "split_0_train_8108_entity",
"type": "progene_text",
"text": [
"transcription factor AP-2"
],
"offsets": [
[
51,
76
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5028
|
split_0_train_5028
|
[
{
"id": "split_0_train_5028_passage",
"type": "progene_text",
"text": [
"There is now evidence from in vivo and in vitro studies that the rate of Schwann cell generation is regulated by the balance of two opposing signals , beta neuregulins and endothelins ."
],
"offsets": [
[
0,
185
]
]
}
] |
[
{
"id": "split_0_train_8109_entity",
"type": "progene_text",
"text": [
"beta neuregulins"
],
"offsets": [
[
151,
167
]
],
"normalized": []
},
{
"id": "split_0_train_8110_entity",
"type": "progene_text",
"text": [
"endothelins"
],
"offsets": [
[
172,
183
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5029
|
split_0_train_5029
|
[
{
"id": "split_0_train_5029_passage",
"type": "progene_text",
"text": [
"The beta neuregulins promote the development of precursors to Schwann cells whereas endothelins retard it through an action on endothelin - B receptors ."
],
"offsets": [
[
0,
153
]
]
}
] |
[
{
"id": "split_0_train_8111_entity",
"type": "progene_text",
"text": [
"beta neuregulins"
],
"offsets": [
[
4,
20
]
],
"normalized": []
},
{
"id": "split_0_train_8112_entity",
"type": "progene_text",
"text": [
"endothelins"
],
"offsets": [
[
84,
95
]
],
"normalized": []
},
{
"id": "split_0_train_8113_entity",
"type": "progene_text",
"text": [
"endothelin - B receptors"
],
"offsets": [
[
127,
151
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5030
|
split_0_train_5030
|
[
{
"id": "split_0_train_5030_passage",
"type": "progene_text",
"text": [
"The present work has shown additional controls of this transition , and implicates AP-2 transcription factors , in particular AP-2 alpha , as negative regulators of Schwann cell generation ."
],
"offsets": [
[
0,
190
]
]
}
] |
[
{
"id": "split_0_train_8114_entity",
"type": "progene_text",
"text": [
"AP-2 transcription factors"
],
"offsets": [
[
83,
109
]
],
"normalized": []
},
{
"id": "split_0_train_8115_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
126,
136
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5031
|
split_0_train_5031
|
[
{
"id": "split_0_train_5031_passage",
"type": "progene_text",
"text": [
"We found that both AP-2 alpha and AP-2 gamma are present in early embryonic nerves , whereas AP-2 beta was not ."
],
"offsets": [
[
0,
112
]
]
}
] |
[
{
"id": "split_0_train_8116_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
19,
29
]
],
"normalized": []
},
{
"id": "split_0_train_8117_entity",
"type": "progene_text",
"text": [
"AP-2 gamma"
],
"offsets": [
[
34,
44
]
],
"normalized": []
},
{
"id": "split_0_train_8118_entity",
"type": "progene_text",
"text": [
"AP-2 beta"
],
"offsets": [
[
93,
102
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5032
|
split_0_train_5032
|
[
{
"id": "split_0_train_5032_passage",
"type": "progene_text",
"text": [
"Isoform - specific analysis of AP-2 alpha showed that isoform 3 was most abundant with isoforms 1 and 2 present in lesser amounts ; isoform 4 was absent ."
],
"offsets": [
[
0,
154
]
]
}
] |
[
{
"id": "split_0_train_8119_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
31,
41
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5033
|
split_0_train_5033
|
[
{
"id": "split_0_train_5033_passage",
"type": "progene_text",
"text": [
"Maximal AP-2 alpha and AP-2 gamma mRNA expression occurred at embryonic day ( E ) 12 / 13 in the mouse and at E14 / 15 in the rat , which correlates with the presence of Schwann cell precursors in the nerve ."
],
"offsets": [
[
0,
208
]
]
}
] |
[
{
"id": "split_0_train_8120_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
8,
18
]
],
"normalized": []
},
{
"id": "split_0_train_8121_entity",
"type": "progene_text",
"text": [
"AP-2 gamma"
],
"offsets": [
[
23,
33
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5034
|
split_0_train_5034
|
[
{
"id": "split_0_train_5034_passage",
"type": "progene_text",
"text": [
"In both rats and in mice , in vivo and in vitro , downregulation of AP-2 alpha mRNA and protein coincided with one of the main steps in Schwann cell development , the precursor - Schwann cell transition ."
],
"offsets": [
[
0,
204
]
]
}
] |
[
{
"id": "split_0_train_8122_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
68,
78
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5035
|
split_0_train_5035
|
[
{
"id": "split_0_train_5035_passage",
"type": "progene_text",
"text": [
"Moreover , Schwann cell generation was delayed if this downregulation was prevented by enforced expression of AP-2 alpha in precursors ."
],
"offsets": [
[
0,
136
]
]
}
] |
[
{
"id": "split_0_train_8123_entity",
"type": "progene_text",
"text": [
"AP-2 alpha"
],
"offsets": [
[
110,
120
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5036
|
split_0_train_5036
|
[
{
"id": "split_0_train_5036_passage",
"type": "progene_text",
"text": [
"These studies suggest that AP-2 is involved in the control of the timing of Schwann cell development ."
],
"offsets": [
[
0,
102
]
]
}
] |
[
{
"id": "split_0_train_8124_entity",
"type": "progene_text",
"text": [
"AP-2"
],
"offsets": [
[
27,
31
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5037
|
split_0_train_5037
|
[
{
"id": "split_0_train_5037_passage",
"type": "progene_text",
"text": [
"Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin - induced antidiuresis ."
],
"offsets": [
[
0,
106
]
]
}
] |
[
{
"id": "split_0_train_8125_entity",
"type": "progene_text",
"text": [
"aquaporin-2"
],
"offsets": [
[
8,
19
]
],
"normalized": []
},
{
"id": "split_0_train_8126_entity",
"type": "progene_text",
"text": [
"vasopressin"
],
"offsets": [
[
70,
81
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5038
|
split_0_train_5038
|
[
{
"id": "split_0_train_5038_passage",
"type": "progene_text",
"text": [
"BACKGROUND :"
],
"offsets": [
[
0,
12
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5039
|
split_0_train_5039
|
[
{
"id": "split_0_train_5039_passage",
"type": "progene_text",
"text": [
"In a state of chronic arginine vasopressin ( AVP ) excess , the action of antidiuresis has been attenuated , resulting in some water diuresis ."
],
"offsets": [
[
0,
143
]
]
}
] |
[
{
"id": "split_0_train_8127_entity",
"type": "progene_text",
"text": [
"arginine vasopressin"
],
"offsets": [
[
22,
42
]
],
"normalized": []
},
{
"id": "split_0_train_8128_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
45,
48
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5040
|
split_0_train_5040
|
[
{
"id": "split_0_train_5040_passage",
"type": "progene_text",
"text": [
"This state has been termed an \" AVP escape \" phenomenon ."
],
"offsets": [
[
0,
57
]
]
}
] |
[
{
"id": "split_0_train_8129_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
32,
35
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5041
|
split_0_train_5041
|
[
{
"id": "split_0_train_5041_passage",
"type": "progene_text",
"text": [
"The present study was designed to determine what mechanisms underlie this attenuation in renal concentrating ability , which is found in chronic AVP excess , both in the presence and absence of volume expansion ."
],
"offsets": [
[
0,
212
]
]
}
] |
[
{
"id": "split_0_train_8130_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
145,
148
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5042
|
split_0_train_5042
|
[
{
"id": "split_0_train_5042_passage",
"type": "progene_text",
"text": [
"METHODS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5043
|
split_0_train_5043
|
[
{
"id": "split_0_train_5043_passage",
"type": "progene_text",
"text": [
"Two groups of experimental rats were established ."
],
"offsets": [
[
0,
50
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5044
|
split_0_train_5044
|
[
{
"id": "split_0_train_5044_passage",
"type": "progene_text",
"text": [
"One group received solid chow with water ad libitum ."
],
"offsets": [
[
0,
53
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5045
|
split_0_train_5045
|
[
{
"id": "split_0_train_5045_passage",
"type": "progene_text",
"text": [
"The second group received chow , which was offered as a liquid diet ."
],
"offsets": [
[
0,
69
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5046
|
split_0_train_5046
|
[
{
"id": "split_0_train_5046_passage",
"type": "progene_text",
"text": [
"Both groups received subcutaneous administration of 1-deamino-8-D-arginine vasopressin ( dDAVP ) at 5 ng / h for the entire observation period of one week ."
],
"offsets": [
[
0,
156
]
]
}
] |
[
{
"id": "split_0_train_8131_entity",
"type": "progene_text",
"text": [
"vasopressin"
],
"offsets": [
[
75,
86
]
],
"normalized": []
},
{
"id": "split_0_train_8132_entity",
"type": "progene_text",
"text": [
"dDAVP"
],
"offsets": [
[
89,
94
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5047
|
split_0_train_5047
|
[
{
"id": "split_0_train_5047_passage",
"type": "progene_text",
"text": [
"Over the course of the observation period , tissue levels of aquaporin-2 ( AQP-2 ) mRNA and protein were measured ."
],
"offsets": [
[
0,
115
]
]
}
] |
[
{
"id": "split_0_train_8133_entity",
"type": "progene_text",
"text": [
"aquaporin-2"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "split_0_train_8134_entity",
"type": "progene_text",
"text": [
"AQP-2"
],
"offsets": [
[
75,
80
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5048
|
split_0_train_5048
|
[
{
"id": "split_0_train_5048_passage",
"type": "progene_text",
"text": [
"Levels of AVP V2 receptor were monitored , both by measuring mRNA levels and by ligand - binding studies using [3H] AVP ."
],
"offsets": [
[
0,
121
]
]
}
] |
[
{
"id": "split_0_train_8135_entity",
"type": "progene_text",
"text": [
"AVP V2 receptor"
],
"offsets": [
[
10,
25
]
],
"normalized": []
},
{
"id": "split_0_train_8136_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
116,
119
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5049
|
split_0_train_5049
|
[
{
"id": "split_0_train_5049_passage",
"type": "progene_text",
"text": [
"Tissue levels of cAMP also were determined ."
],
"offsets": [
[
0,
44
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5050
|
split_0_train_5050
|
[
{
"id": "split_0_train_5050_passage",
"type": "progene_text",
"text": [
"RESULTS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5051
|
split_0_train_5051
|
[
{
"id": "split_0_train_5051_passage",
"type": "progene_text",
"text": [
"Experimental rats with the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) had severe hyponatremia below 120 mmol / L , and impaired urinary concentrating ability , during the seven - day observation period ."
],
"offsets": [
[
0,
230
]
]
}
] |
[
{
"id": "split_0_train_8137_entity",
"type": "progene_text",
"text": [
"antidiuretic hormone"
],
"offsets": [
[
66,
86
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5052
|
split_0_train_5052
|
[
{
"id": "split_0_train_5052_passage",
"type": "progene_text",
"text": [
"In contrast , the dDAVP - excess rats , given solid chow , maintained maximally concentrated urine and normal levels of serum sodium ."
],
"offsets": [
[
0,
134
]
]
}
] |
[
{
"id": "split_0_train_8138_entity",
"type": "progene_text",
"text": [
"dDAVP"
],
"offsets": [
[
18,
23
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5053
|
split_0_train_5053
|
[
{
"id": "split_0_train_5053_passage",
"type": "progene_text",
"text": [
"The down - regulation of AVP V2 receptor function was comparable in the two groups ."
],
"offsets": [
[
0,
84
]
]
}
] |
[
{
"id": "split_0_train_8139_entity",
"type": "progene_text",
"text": [
"AVP V2 receptor"
],
"offsets": [
[
25,
40
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5054
|
split_0_train_5054
|
[
{
"id": "split_0_train_5054_passage",
"type": "progene_text",
"text": [
"The maximal binding capacity ( Bmax ) fell to the nadir on day 2 and was thereafter suppressed at approximately 60 % of control rats during the experiment ."
],
"offsets": [
[
0,
156
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5055
|
split_0_train_5055
|
[
{
"id": "split_0_train_5055_passage",
"type": "progene_text",
"text": [
"Up - regulation of AQP-2 mRNA expression was found , but this up - regulation was significantly less in the SIADH rats compared with the dDAVP - excess rats ( 153.5 +/- 29.8 % vs. 323.7 +/- 23.8 % on day 7 , P < 0.05 ) ."
],
"offsets": [
[
0,
220
]
]
}
] |
[
{
"id": "split_0_train_8140_entity",
"type": "progene_text",
"text": [
"AQP-2"
],
"offsets": [
[
19,
24
]
],
"normalized": []
},
{
"id": "split_0_train_8141_entity",
"type": "progene_text",
"text": [
"dDAVP"
],
"offsets": [
[
137,
142
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5056
|
split_0_train_5056
|
[
{
"id": "split_0_train_5056_passage",
"type": "progene_text",
"text": [
"This differential response between these two groups was affirmed by measured differences in AQP-2 protein levels , both in tissue and in urinary excretion ."
],
"offsets": [
[
0,
156
]
]
}
] |
[
{
"id": "split_0_train_8142_entity",
"type": "progene_text",
"text": [
"AQP-2"
],
"offsets": [
[
92,
97
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5057
|
split_0_train_5057
|
[
{
"id": "split_0_train_5057_passage",
"type": "progene_text",
"text": [
"CONCLUSIONS :"
],
"offsets": [
[
0,
13
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5058
|
split_0_train_5058
|
[
{
"id": "split_0_train_5058_passage",
"type": "progene_text",
"text": [
"These results indicate that the attenuated regulation of the AQP-2 gene leads to the decrease in urinary concentrating ability in the experimental SIADH rats , suffering from hypervolemic state , compared with the normonatremic rats receiving AVP ."
],
"offsets": [
[
0,
248
]
]
}
] |
[
{
"id": "split_0_train_8143_entity",
"type": "progene_text",
"text": [
"AQP-2"
],
"offsets": [
[
61,
66
]
],
"normalized": []
},
{
"id": "split_0_train_8144_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
243,
246
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5059
|
split_0_train_5059
|
[
{
"id": "split_0_train_5059_passage",
"type": "progene_text",
"text": [
"Either hypervolemia or hypotonicity may diminish the post - receptor signaling of AVP in renal collecting duct cells , under the chronic AVP excess state found in SIADH ."
],
"offsets": [
[
0,
170
]
]
}
] |
[
{
"id": "split_0_train_8145_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
82,
85
]
],
"normalized": []
},
{
"id": "split_0_train_8146_entity",
"type": "progene_text",
"text": [
"AVP"
],
"offsets": [
[
137,
140
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5060
|
split_0_train_5060
|
[
{
"id": "split_0_train_5060_passage",
"type": "progene_text",
"text": [
"Management of hepatitis C virus - related arthritis ."
],
"offsets": [
[
0,
53
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5061
|
split_0_train_5061
|
[
{
"id": "split_0_train_5061_passage",
"type": "progene_text",
"text": [
"Hepatitis C virus ( HCV ) infection is often associated with extrahepatic manifestations among which arthropathy is common , affecting up to 20 % of HCV - infected individuals ."
],
"offsets": [
[
0,
177
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5062
|
split_0_train_5062
|
[
{
"id": "split_0_train_5062_passage",
"type": "progene_text",
"text": [
"This arthropathy is to be distinguished from the more superficially prominent myalgias and fatigue ."
],
"offsets": [
[
0,
100
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5063
|
split_0_train_5063
|
[
{
"id": "split_0_train_5063_passage",
"type": "progene_text",
"text": [
"HCV - related arthritis is commonly presented as rheumatoid - like , symmetrical inflammatory polyarthritis involving mainly small joints , or , less commonly , as mono - or oligoarthritis , usually of the large joints ."
],
"offsets": [
[
0,
220
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5064
|
split_0_train_5064
|
[
{
"id": "split_0_train_5064_passage",
"type": "progene_text",
"text": [
"HCV arthritis usually runs a relatively benign course that , in contrast to ' true ' rheumatoid arthritis ( RA ) , is typically non - deforming and is not associated with articular bony erosions ."
],
"offsets": [
[
0,
196
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5065
|
split_0_train_5065
|
[
{
"id": "split_0_train_5065_passage",
"type": "progene_text",
"text": [
"In addition , unlike ' classic ' RA , erythrocyte sedimentation rate is elevated only in about half of the patients and subcutaneous nodules are absent ."
],
"offsets": [
[
0,
153
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5066
|
split_0_train_5066
|
[
{
"id": "split_0_train_5066_passage",
"type": "progene_text",
"text": [
"In about two - thirds of the affected individuals morning stiffness may be severe , resolving after more than an hour ."
],
"offsets": [
[
0,
119
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5067
|
split_0_train_5067
|
[
{
"id": "split_0_train_5067_passage",
"type": "progene_text",
"text": [
"Several pathogenetic mechanisms may be involved : HCV arthritis may be part of the syndrome of mixed cryoglobulinaemia , or may be directly or indirectly mediated by HCV ."
],
"offsets": [
[
0,
171
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5068
|
split_0_train_5068
|
[
{
"id": "split_0_train_5068_passage",
"type": "progene_text",
"text": [
"Such possible , but yet not proven , mechanisms include direct invasion of synovial cells by the virus eliciting local inflammatory response , cytokine - induced disease or immune complex disease , particularly in genetically susceptible individuals ."
],
"offsets": [
[
0,
251
]
]
}
] |
[
{
"id": "split_0_train_8147_entity",
"type": "progene_text",
"text": [
"cytokine"
],
"offsets": [
[
143,
151
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5069
|
split_0_train_5069
|
[
{
"id": "split_0_train_5069_passage",
"type": "progene_text",
"text": [
"The diagnosis of HCV arthritis in patients with positive rheumatoid factor and chronic inflammatory polyarthritis may be difficult ."
],
"offsets": [
[
0,
132
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5070
|
split_0_train_5070
|
[
{
"id": "split_0_train_5070_passage",
"type": "progene_text",
"text": [
"Positive HCV antibody and HCV RNA , and the absence of bony erosions , subcutaneous nodules and antikeratin antibodies , may be useful in distinguishing between HCV - related arthritis and RA ."
],
"offsets": [
[
0,
193
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5071
|
split_0_train_5071
|
[
{
"id": "split_0_train_5071_passage",
"type": "progene_text",
"text": [
"The optimal treatment of HCV - related arthritis has not yet been established ."
],
"offsets": [
[
0,
79
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5072
|
split_0_train_5072
|
[
{
"id": "split_0_train_5072_passage",
"type": "progene_text",
"text": [
"Concerns may be raised regarding the use of immunosuppressive or potentially hepatotoxic drugs ."
],
"offsets": [
[
0,
96
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5073
|
split_0_train_5073
|
[
{
"id": "split_0_train_5073_passage",
"type": "progene_text",
"text": [
"However , it may be suggested that once the diagnosis of HCV - associated arthritis is made , combination antiviral treatment with interferon-alpha and ribavirin should be initiated as part of the therapeutic armamentarium ."
],
"offsets": [
[
0,
224
]
]
}
] |
[
{
"id": "split_0_train_8148_entity",
"type": "progene_text",
"text": [
"interferon-alpha"
],
"offsets": [
[
131,
147
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5074
|
split_0_train_5074
|
[
{
"id": "split_0_train_5074_passage",
"type": "progene_text",
"text": [
"Low dose oral corticosteroids , nonsteroidal anti - inflammatory drugs , hydroxychloroquine or sulfasalazine in addition to the antiviral therapy can be used to control arthritis - related symptoms ."
],
"offsets": [
[
0,
199
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5075
|
split_0_train_5075
|
[
{
"id": "split_0_train_5075_passage",
"type": "progene_text",
"text": [
"Some patients may need long term anti - inflammatory treatment in various combinations , along with antiviral therapy ."
],
"offsets": [
[
0,
119
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5076
|
split_0_train_5076
|
[
{
"id": "split_0_train_5076_passage",
"type": "progene_text",
"text": [
"In patients with severe , disabling or life - threatening cryoglobulinaemia - related symptoms refractory to antiviral or anti - inflammatory treatment , high dose corticosteroids ( including pulse therapy ) and/or plasmapheresis may be needed ."
],
"offsets": [
[
0,
245
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5077
|
split_0_train_5077
|
[
{
"id": "split_0_train_5077_passage",
"type": "progene_text",
"text": [
"Histone deacetylase as a new target for cancer chemotherapy ."
],
"offsets": [
[
0,
61
]
]
}
] |
[
{
"id": "split_0_train_8149_entity",
"type": "progene_text",
"text": [
"Histone deacetylase"
],
"offsets": [
[
0,
19
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5078
|
split_0_train_5078
|
[
{
"id": "split_0_train_5078_passage",
"type": "progene_text",
"text": [
"Trichostatin A ( TSA ) and trapoxin ( TPX ) , inhibitors of the eukaryotic cell cycle and inducers of morphological reversion of transformed cells , inhibit histone deacetylase ( HDAC ) at nanomolar concentrations ."
],
"offsets": [
[
0,
215
]
]
}
] |
[
{
"id": "split_0_train_8150_entity",
"type": "progene_text",
"text": [
"histone deacetylase"
],
"offsets": [
[
157,
176
]
],
"normalized": []
},
{
"id": "split_0_train_8151_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
179,
183
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5079
|
split_0_train_5079
|
[
{
"id": "split_0_train_5079_passage",
"type": "progene_text",
"text": [
"Recently , FK228 ( also known as FR901228 and depsipeptide ) and MS-275 ."
],
"offsets": [
[
0,
73
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5080
|
split_0_train_5080
|
[
{
"id": "split_0_train_5080_passage",
"type": "progene_text",
"text": [
"antitumor agents structurally unrelated to TSA , have been shown to be potent HDAC inhibitors ."
],
"offsets": [
[
0,
95
]
]
}
] |
[
{
"id": "split_0_train_8152_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
78,
82
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5081
|
split_0_train_5081
|
[
{
"id": "split_0_train_5081_passage",
"type": "progene_text",
"text": [
"These inhibitors activate the expression of p21Waf1 in a p53 - independent manner ."
],
"offsets": [
[
0,
83
]
]
}
] |
[
{
"id": "split_0_train_8153_entity",
"type": "progene_text",
"text": [
"p21Waf1"
],
"offsets": [
[
44,
51
]
],
"normalized": []
},
{
"id": "split_0_train_8154_entity",
"type": "progene_text",
"text": [
"p53"
],
"offsets": [
[
57,
60
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5082
|
split_0_train_5082
|
[
{
"id": "split_0_train_5082_passage",
"type": "progene_text",
"text": [
"Changes in the expression of regulators of the cell cycle , differentiation , and apoptosis with increased histone acetylation may be responsible for the cell cycle arrest and antitumor activity of HDAC inhibitors ."
],
"offsets": [
[
0,
215
]
]
}
] |
[
{
"id": "split_0_train_8155_entity",
"type": "progene_text",
"text": [
"histone"
],
"offsets": [
[
107,
114
]
],
"normalized": []
},
{
"id": "split_0_train_8156_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
198,
202
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5083
|
split_0_train_5083
|
[
{
"id": "split_0_train_5083_passage",
"type": "progene_text",
"text": [
"TSA has been suggested to block the catalytic reaction by chelating a zinc ion in the active site pocket through its hydroxamic acid group ."
],
"offsets": [
[
0,
140
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5084
|
split_0_train_5084
|
[
{
"id": "split_0_train_5084_passage",
"type": "progene_text",
"text": [
"On the other hand , an epoxyketone has been suggested to be the functional group of TPX capable of alkylating the enzyme ."
],
"offsets": [
[
0,
122
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5085
|
split_0_train_5085
|
[
{
"id": "split_0_train_5085_passage",
"type": "progene_text",
"text": [
"We synthesized a novel TPX analogue containing a hydroxamic acid instead of the epoxyketone ."
],
"offsets": [
[
0,
93
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5086
|
split_0_train_5086
|
[
{
"id": "split_0_train_5086_passage",
"type": "progene_text",
"text": [
"The hybrid compound , called cyclic hydroxamic - acid - containing peptide 1 ( CHAP1 ) inhibited HDAC at low nanomolar concentrations ."
],
"offsets": [
[
0,
135
]
]
}
] |
[
{
"id": "split_0_train_8157_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
97,
101
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5087
|
split_0_train_5087
|
[
{
"id": "split_0_train_5087_passage",
"type": "progene_text",
"text": [
"The HDAC1 inhibition by CHAPI was reversible , as is that by TSA , in contrast to irreversible inhibition by TPX ."
],
"offsets": [
[
0,
114
]
]
}
] |
[
{
"id": "split_0_train_8158_entity",
"type": "progene_text",
"text": [
"HDAC1"
],
"offsets": [
[
4,
9
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5088
|
split_0_train_5088
|
[
{
"id": "split_0_train_5088_passage",
"type": "progene_text",
"text": [
"Interestingly , HDAC6 , but not HDAC1 or HDAC4 , was resistant to TPX and CHAP1 , while TSA inhibited these HDACs to a similar degree ."
],
"offsets": [
[
0,
135
]
]
}
] |
[
{
"id": "split_0_train_8159_entity",
"type": "progene_text",
"text": [
"HDAC6"
],
"offsets": [
[
16,
21
]
],
"normalized": []
},
{
"id": "split_0_train_8160_entity",
"type": "progene_text",
"text": [
"HDAC1"
],
"offsets": [
[
32,
37
]
],
"normalized": []
},
{
"id": "split_0_train_8161_entity",
"type": "progene_text",
"text": [
"HDAC4"
],
"offsets": [
[
41,
46
]
],
"normalized": []
},
{
"id": "split_0_train_8162_entity",
"type": "progene_text",
"text": [
"HDACs"
],
"offsets": [
[
108,
113
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5089
|
split_0_train_5089
|
[
{
"id": "split_0_train_5089_passage",
"type": "progene_text",
"text": [
"CHAP31 , the strongest HDAC inhibitor obtained from a variety of CHAP derivatives , exhibited antitumor activity in BDF1 mice bearing B16 / BL6 tumor cells ."
],
"offsets": [
[
0,
157
]
]
}
] |
[
{
"id": "split_0_train_8163_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
23,
27
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5090
|
split_0_train_5090
|
[
{
"id": "split_0_train_5090_passage",
"type": "progene_text",
"text": [
"These results suggest that CHAP31 is promising as a novel therapeutic agent for cancer treatment , and that CHAP may serve as a basis for new HDAC inhibitors and be useful for combinatorial synthesis and high - throughput screening ."
],
"offsets": [
[
0,
233
]
]
}
] |
[
{
"id": "split_0_train_8164_entity",
"type": "progene_text",
"text": [
"HDAC"
],
"offsets": [
[
142,
146
]
],
"normalized": []
}
] |
[] |
[] |
[] |
split_0_train_5091
|
split_0_train_5091
|
[
{
"id": "split_0_train_5091_passage",
"type": "progene_text",
"text": [
"Evaluation of glaucomatous visual field loss with locally condensed grids using fundus - oriented perimetry ( FOP ) ."
],
"offsets": [
[
0,
117
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5092
|
split_0_train_5092
|
[
{
"id": "split_0_train_5092_passage",
"type": "progene_text",
"text": [
"PURPOSE :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5093
|
split_0_train_5093
|
[
{
"id": "split_0_train_5093_passage",
"type": "progene_text",
"text": [
"We compared detection rates of glaucomatous visual field defects ( VFDs ) between a conventional rectangular stimulus grid and locally condensed test point arrangements in morphologically suspicious regions ."
],
"offsets": [
[
0,
208
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5094
|
split_0_train_5094
|
[
{
"id": "split_0_train_5094_passage",
"type": "progene_text",
"text": [
"METHODS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5095
|
split_0_train_5095
|
[
{
"id": "split_0_train_5095_passage",
"type": "progene_text",
"text": [
"Humphrey Field Analyzer model 630 ( HFA I , program 30 - 2 with a rectangular 6 degrees x 6 degrees grid ) was used as the conventional perimetric method ."
],
"offsets": [
[
0,
155
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5096
|
split_0_train_5096
|
[
{
"id": "split_0_train_5096_passage",
"type": "progene_text",
"text": [
"Individual local test - point condensation was realized by fundus - oriented perimetry ( FOP ) on the Tuebingen Computer Campimeter ( TCC ) ."
],
"offsets": [
[
0,
141
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5097
|
split_0_train_5097
|
[
{
"id": "split_0_train_5097_passage",
"type": "progene_text",
"text": [
"RESULTS :"
],
"offsets": [
[
0,
9
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5098
|
split_0_train_5098
|
[
{
"id": "split_0_train_5098_passage",
"type": "progene_text",
"text": [
"Of a total of 66 glaucoma patients , or suspected sufferers , 23 showed normal findings and 27 showed pathological findings with both methods ."
],
"offsets": [
[
0,
143
]
]
}
] |
[] |
[] |
[] |
[] |
split_0_train_5099
|
split_0_train_5099
|
[
{
"id": "split_0_train_5099_passage",
"type": "progene_text",
"text": [
"In 15 cases we found normal visual fields in HFA 30 - 2 , whereas FOP revealed early glaucomatous functional damage ."
],
"offsets": [
[
0,
117
]
]
}
] |
[] |
[] |
[] |
[] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.